Results 131 to 140 of about 530,731 (290)
The evolution of bispecific antibodies [PDF]
Expert Opinion on Biological Therapy, 2022 openaire +2 more sources
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells
Allergy, EarlyView.We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller +16 more
wiley +1 more source
Andrology, EarlyView.ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick +7 more
wiley +1 more source
Intravitreal faricimab in patients with nAMD: French data from the Fight Retinal Blindness! Registry
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess real‐world outcomes of intravitreal faricimab in French patients with neovascular age‐related macular degeneration (nAMD) previously treated with vascular endothelial growth factor (VEGF) inhibitors using data from the Fight Retinal Blindness! (FRB!) Registry.
Eloi Debourdeau +11 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo +3 more
wiley +1 more source
Journal of Biological EngineeringBackground Bispecific antibodies that redirect T cells or NK cells to tumors have demonstrated substantial therapeutic efficacy, but their broader application is often constrained by immune-related toxicities, limited effector cell availability, and ...
Jisun Lee +5 more
doaj +1 more source
British Journal of Haematology, EarlyView.In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend +16 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary The extensive use of lenalidomide (Len) in the first‐line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len‐R) at first relapse. However, the outcome of Len‐R patients treated at first relapse after autologous haematopoietic stem cell transplantation (AHSCT)
Gregorio Barilà +48 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and ...
Irene Strassl +23 more
wiley +1 more source